22 oktober 2025: Zie ook dit artikel: https://kanker-actueel.nl/NL/ctdna-circulerend-tumor-dna-via-bloed-verkregen-toont-in-de-klinische-praktijk-geen-meerwaarde-tov-chemotherapie-maar-afbouwen-van-chemotherapie-na-negatieve-ctdna-test-speelt-daarin-cruciale-rol.html
24 januari 2025: zie ook dit artikel: https://kanker-actueel.nl/ctdna-circulerend-tumor-dna-is-uitstekende-biomarker-voor-wel-of-geen-toekomstig-recidief-na-operatie-en-of-chemotherapie-bij-endeldarmkanker-rectumkanker-blijkt-uit-meta-analyse.html
24 januari 2025: Bron: Annals of Oncology, Volume 35, Issue 5, May 2024, Pages 476-477
Een multimodale ctDNA test die de resultaten uit het bloed samenvoegt met resultaten uit erfelijkheidsonderzoek en genetisch onderzoek (genomica, epigenetica en fragmentomics en proteomics (eiwitexprressie)) blijkt bij mensen in Barcelona die positief scoorden bij een fecal immunochemical test (FIT) nauwkeurig het stadium van de aanwezige darmkankertumoren te registreren.
Totaal 623 bloedmonsters verkregen via een ctDNA test werden geanalyseerd in de primaire analyse. Gevoeligheid en specificiteit van de gebruikte test om darmkanker vast te stellen was 93% en 90%, respectievelijk in de vergelijking met patiënten met reeds eerder vastgestelde darmkanker in een Spaanse studie.
De gevoeligheid om de stadia van de darmkankertumoren vast te stellen was 84% voor stadium I, 94% voor stadium II en 96% voor stadium III (70/73).
Een tweede doel van de studie was om gevorderde kwaadaardige poliepen te ontdekken en bleek bij 23 procent vast te stellen .
Dit zijn de kernpunten van de studie:
- De effectiviteit van CRC-screeningprogramma's wordt beperkt door de lage naleving van screeningaanbevelingen door de bevolking.
- Een nieuwe bloedmultimodale ctDNA-gebaseerde test werd getest bij FIT-positieve personen uit een screeningprogramma en CRC-patiënten.
- CRC werd met hoge nauwkeurigheid gedetecteerd (93% gevoeligheid; 90% specificiteit). De gevoeligheid om precancereuze laesies te detecteren was 23%.
- Een bloedtest met genomica, epigenomica, fragmentomica en proteomica kan de effectiviteit van CRC-screening vergroten.
De onderzoekers stellen dan ook dat deze multimodale ctDNA test samengevoegd met resultaten uit erfelijkheidsonderzoek en genetisch onderzoek goed gebruikt zou kunnen worden bij het bevolkingsonderzoek darmkanker.
Het volledige studierapport is gratis in te zien of te downloaden. Klik daarvoor op de titel van het abstract:
Annals of Oncology
Volume 34, Issue 12, December 2023, Pages 1187-1193
Original Article
High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer
Under a Creative Commons license
open access
Referred to by
Annals of Oncology, Volume 35, Issue 5, May 2024, Pages 476-477
H. Brenner, T. Niedermaier, M. Hoffmeister
Disclosure
JV reports personal fees from Merck, Amgen, Sanofi, Bristol Myers Squibb and Pierre Fabre outside the submitted work. BB reports grants from ThermoFisher, Roche Diagnostics, Roche Farma and AstraZeneca; and personal fees from Amgen, AstraZeneca, Janssen, Novartis, Merck-Serono, Qiagen, ThermoFisher, Pfizer and Bristol Myers Squibb. CM reports grants from Merck-Serono, Amgen and Roche; and personal fees from Amgen, Lilly, Merck-Serono, Sanofi and Biocartis outside the submitted work. All other authors have declared no conflicts of interest.
Funding
This study was supported by Project “PI21/00041”, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union and by “CRIS EXCELLENCE19-30”, funded by CRIS Contra el Cáncer.
Artikelen waarin genoemde studie is geciteerd:
Artikelen waarin genoemde studie is geciteerd:
| Document title | Authors | Year | Source | Cited by | |
|---|---|---|---|---|---|
| Whole-genome sequencing of cell-free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas Open Access
|
Frydendahl, A., Widman, A.J., Øgaard, N., (...), Landau, D.A., Andersen, C.L. | 2025 | Molecular Oncology Article in Press |
0 | |
| Assessing the Causal Effect of Circulating Protein-To-Protein Ratio on the Risk of Morbidity of Hepatocellular Carcinoma Open Access
|
Yue, Q., Li, X., Wan, X., (...), Zhang, M., Xu, S. | 2025 | Cancer Medicine | 0 | |
| Utilization of molecular genetic approaches for colorectal cancer screening | Emelyanova, M.A., Ikonnikova, A.Y. | 2024 | World Journal of Gastroenterology | 0 | |
| Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interface | Haddad, T.S., Bokhorst, J.M., Berger, M.D., (...), Lugli, A., Nagtegaal, I.D. | 2024 | Journal of Translational Medicine | 0 | |
| Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer | Roazzi, L., Patelli, G., Bencardino, K.B., (...), Siena, S., Sartore-Bianchi, A. | 2024 | Clinical Colorectal Cancer | 4 | |
| Clinical Applications of Circulating Tumor DNA Profiling in GI Cancers | Battaglin, F., Lenz, H.-J. | 2024 | JCO Oncology Practice | 1 | |
| Biomarkers in Colorectal Cancer: Actual and Future Perspectives Open Access
|
Lișcu, H.-D., Verga, N., Atasiei, D.-I., (...), Manole, D.-C., Ionescu, A.-I. | 2024 | International Journal of Molecular Sciences | 0 | |
| Progress in research of proteomics related to digestive system tumor markers | [消化系统肿瘤标志物相关蛋白组学的研究进展] Open Access
|
Cai, X.-H., Zhao, S.-Q., Zhang, K., Liu, W.-T. | 2024 | World Chinese Journal of Digestology | 0 | |
| Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer | Cao, Y., Wang, N., Wu, X., (...), Bao, J., Yang, L. | 2024 | Cancer Research | 2 | |
| Early diagnostic strategies for colorectal cancer Open Access
|
Liu, S.-C., Zhang, H. | 2024 | World Journal of Gastroenterology | 0 | |
| Ultra-Sensitive Detection of the SARS-CoV-2 Nucleocapsid Protein via a Clustered Regularly Interspaced Short Palindromic Repeat/Cas12a-Mediated Immunoassay | Yin, W., Li, L., Yang, Y., (...), Mao, G., Ma, Y. | 2024 | ACS Sensors | 5 | |
| Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials Open Access
|
Conca, V., Ciracì, P., Boccaccio, C., (...), Antoniotti, C., Cremolini, C. | 2024 | Cancer Treatment Reviews | 5 | |
| Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms | Brenner, H., Niedermaier, T., Hoffmeister, M. | 2024 | Annals of Oncology | 0 | |
| Mapping the Future: A Comprehensive Bibliometric Analysis of Circulating Tumor DNA in Colorectal Cancer Open Access
|
Wang, C. | 2024 | Journal of Multidisciplinary Healthcare | 0 | |
| Utility of circulating tumor DNA in secondary liver malignancies: What we know and what is to come Open Access
|
Wehrle, C.J., Tocci, N.X., Sun, K., (...), Kwon, D.C.H., Aucejo, F. | 2024 | Journal of Surgical Oncology Article in Press |
0 | |
| A Review on Emerging Techniques for Diagnosis of Colorectal Cancer | Nagainallur Ravichandran, S., Das, D., Dayananda, E.K., (...), Sun, X.-F., Pathak, S. | 2024 | Cancer Investigation | 0 | |
References
- 1
Cancer statistics, 2023CA Cancer J Clin, 73 (2023), pp. 17-48
- 2
Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future ratesCancer, 116 (2010), pp. 544-573
- 3
Colonoscopic polypectomy and long-term prevention of colorectal-cancer deathsN Engl J Med, 366 (2012), pp. 687-696
- 4
Colorectal cancer screening by fecal immunochemical test or colonoscopy in France: how many people are actually covered? Focus on the Provence-Alpes-Côte d’Azur regionEur J Gastroenterol Hepatol, 34 (2022), pp. 405-410
- 5
Impact of patient adherence to stool-based colorectal cancer screening and colonoscopy following a positive test on clinical outcomesCancer Prev Res (Phila), 14 (2021), pp. 845-850
- 6
Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a medicaid populationPrev Med Rep, 30 (2022), Article 102032
- 7
Modifiable failures in the colorectal cancer screening process and their association with risk of deathGastroenterology, 156 (2019), pp. 63-74.e6
- 8
Strategies for colorectal cancer screeningGastroenterology, 158 (2020), pp. 418-432
- 9
Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion: a randomized clinical trialJ Am Med Assoc, 318 (2017), pp. 806-815
- 10
Effects of attendance to an organized fecal immunochemical test screening program on the risk of colorectal cancer: an observational cohort studyClin Gastroenterol Hepatol, 20 (2022), pp. 2373-2382
- 11
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publicationEndoscopy, 45 (2013), pp. 51-59
- 12
Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018Cancer, 121 (2015), pp. 2281-2285
- 13
Optimising colorectal cancer screening acceptance: a reviewGut, 64 (2015), pp. 1158-1177
- 14
Reduced and full-preparation CT colonography, fecal immunochemical test, and colonoscopy for population screening of colorectal cancer: a randomized trialJ Natl Cancer Inst, 108 (2015), Article djv319
- 15
Adherence to colorectal cancer screening: a randomized clinical trial of competing strategiesArch Intern Med, 172 (2012), pp. 575-582
- 16
Colonoscopy versus fecal immunochemical testing in colorectal-cancer screeningN Engl J Med, 366 (2012), pp. 697-706
- 17
Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling studyBrit Med J, 367 (2019), Article l5383
- 18
Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps: a systematic review and meta-analysisAnn Intern Med, 170 (2019), pp. 319-329
- 19
Effect of sex, age, and positivity threshold on fecal immunochemical test accuracy: a systematic review and meta-analysisGastroenterology, 157 (2019), pp. 1494-1505
- 20
Multitarget stool DNA testing for colorectal-cancer screeningN Engl J Med, 370 (2014), pp. 1287-1297
- 21
Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in GermanyBMC Gastroenterol, 14 (2014), p. 183
- 22
Screening for prostate cancer: US preventive services task force recommendation statementJ Am Med Assoc, 319 (2018), pp. 1901-1913
- 23
A novel cell-free DNA methylation-based model improves the early detection of colorectal cancerMol Oncol, 15 (2021), pp. 2702-2714
- 24
Direct detection of early-stage cancers using circulating tumor DNASci Transl Med, 9 (2017), Article eaan2415
- 25
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancerGut, 63 (2014), pp. 317-325
- 26
Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancerBMC Med, 9 (2011), p. 133
- 27
[Colorectal Cancer Early Screening Program of Barcelona, Spain: Indicators of the first round of a program with participation of community pharmacies]Med Clin (Barc), 145 (2015), pp. 141-146
- 28
Chapter 20 - Colon and rectumAJCC Cancer Staging Manual (8th ed.), Springer, New York, NY (2017)
- 29
Detection and localization of surgically resectable cancers with a multi-analyte blood testScience (1979), 359 (2018), pp. 926-930
- 30
Clinical applications of liquid biopsy in colorectal cancer screening: current challenges and future perspectivesCells, 11 (2022), p. 3493
- 31
Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasiaBMC Cancer, 15 (2015), p. 654
- 32
Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancerSci Transl Med, 12 (2020), Article eaax7533
- 33
Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screeningCancer Med, 8 (2019), pp. 5619-5628
- 34
Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trialClin. Cancer Res, 27 (2021), pp. 2890-2898
Gerelateerde artikelen
- ctDNA in het bloed van patiënten met endeldarmkanker en dikke darmkanker wordt meer en meer toegepast. Hier een overzicht en enkele lopende studies met ctDNA
- ctDNA: multimodale ctDNA bloedtest die genomica en epigenetica integreert in combinatie met proteomics constateert 84 tot 96 procent juiste stadium van darmkanker na verdenking in screening en bevolkingsonderzoek
- ctDNA - circulerend tumor DNA is uitstekende biomarker voor wel of geen toekomstig recidief na operatie en of chemotherapie bij endeldarmkanker - rectumkanker blijkt uit meta-analyse
- ctDNA - circulerend tumor-DNA via bloed verkregen toont in de klinische praktijk geen meerwaarde t.o.v. chemotherapie maar afbouwen van chemotherapie na negatieve ctDNA test speelt daarin cruciale rol
Plaats een reactie ...
Reageer op "ctDNA: multimodale ctDNA bloedtest die genomica en epigenetica integreert in combinatie met proteomics constateert 84 tot 96 procent juiste stadium van darmkanker na verdenking in screening en bevolkingsonderzoek"